The trial is public. The IDE isn't.

A sponsor files an investigational device exemption for a significant-risk trial, and FDA will not confirm that the application exists. Under 21 CFR 812.38(a), an IDE’s existence stays confidential unless the sponsor has already disclosed it publicly, or until FDA approves the resulting PMA or a product development protocol’s completion notice takes effect. For most devices still in trial, that is years of silence from the agency’s side of the file.

The trial running under that same IDE number can be a different story entirely.

What FDAAA 801 actually requires

Title VIII of the FDA Amendments Act of 2007 — usually cited as FDAAA 801 — amended the Public Health Service Act at 42 U.S.C. § 282(j) to require registration, and in some cases results reporting, for a defined category of clinical trials. HHS’s implementing final rule, Clinical Trials Registration and Results Information Submission (81 FR 64981, Sept. 21, 2016), took effect January 18, 2017, with a compliance date of April 18, 2017, and is codified at 42 CFR Part 11.

For a device study, 42 CFR 11.22(b)(1)(ii) defines an “applicable device clinical trial” as a prospective, interventional study whose primary purpose is something other than feasibility, that studies an FDA-regulated device, and that clears at least one of three jurisdictional hooks: a site in the United States or a U.S. territory, a device manufactured in the U.S. and exported for a study abroad, or — the one that matters here — conduct under an investigational device exemption.

Once a study meets that test, 42 CFR 11.24(a) sets the clock: the responsible party must submit registration information to ClinicalTrials.gov no later than 21 calendar days after the first human subject is enrolled. “Enrolled” has its own definition, in 42 CFR 11.10(a) — it means a subject has completed informed consent, not merely been screened. Later edits to the registration don’t restart that clock; it runs from first enrollment and keeps running.

What doesn’t have to register

The rule carves out one category by design: a small clinical trial run to determine a device’s feasibility, or a prototype study whose primary outcome measure is feasibility rather than a health outcome, both defined in 42 CFR 11.10(a) alongside the enrollment definition. A sponsor running an early feasibility study under its IDE can keep that study, like the IDE itself, out of any public registry. The same sponsor’s pivotal study, filed months later under the identical IDE number, has no such exemption once it is interventional and aimed at a health outcome rather than a feasibility question.

The IDE number is confidential by regulation. The pivotal trial run under it is required by a different regulation to be public within three weeks of the first patient signing consent.

Nothing links the two records to each other publicly — FDA doesn’t publish the IDE number on the ClinicalTrials.gov record, and the registry doesn’t require one. But a device, a sponsor, and a clinical program — name, device description, condition studied, sites, estimated enrollment, target completion date — become visible on one federal database well before FDA will confirm anything at all on the other.

The practice

A tracked product’s clinical trial registration is not one of the four sources FDA Radar ingests — Federal Register notices, warning letters, device recalls, and 510(k) clearances. If a competitor’s device is running a pivotal IDE study, that study’s public record lives at ClinicalTrials.gov, not in anything this product checks, and a portfolio watch here will not surface it. This is regulatory intelligence and method, never regulatory advice about what a specific trial registration does or doesn’t reveal about a sponsor’s timeline — that reading is the kind of judgment a clinical-trial-intelligence service, not a device-monitoring one, is built to make.